A Closer Look: Alogliptin's Delay Accelerated Takeda's Pursuit Of Nycomed
This article was originally published in The Pink Sheet Daily
Takeda found itself desperate to fill gaps with Actos LOE looming and alogliptin faltering, hastening a 10-year conversation with Nycomed.
You may also be interested in...
Following through on a goal to expand operations in one of the world's fastest growing markets, Nycomed AS confirmed Nov. 1 that it is beefing up its Chinese presence through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma
Takeda announced June 27 that U.S. FDA had denied approval of its type 2 diabetes agent alogliptin, a potential blockbuster poised to compete with similar molecules from Merck and the team of Bristol-Myers Squibb and AstraZeneca. The setback will delay alogliptin's launch by at least three years - and possibly longer - depending on the additional studies required by regulators
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?